Accordingly, there is growing interest in understanding the diuretic and natriuretic properties of contemporary medical therapies such as sodium glucose cotransporter 2 (SGLT2) inhibitors, carbonic anhydrase (CA) inhibitors, thiazide diuretics, and mineralocorticoid receptor (MR) antagonists, and their roles in managing volume overload in HF, especially as adjuncts to loop diuretic therapy. This evidence concerns the gene SLC5A2 and hydrops fetalis.